A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study.
A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group Study.
复制标题
苔藓抑素-1 (NSC) 的随机 II 期评估
DOI：
10.1023/a:1025490818450
复制
发表时间：
2003
影响因子：
3.4
通讯作者：
Nunez,EvelynR
中科院分区：
文献类型：
--
作者：
Armstrong,DeborahK;Blessing,JohnA;Look,KatherineY;Schilder,Russell;Nunez,EvelynR
Objectives. The Gynecologic Oncology Group (GOG) performed a randomized phase II study to determine the antitumor activity and toxicity of two different schedules of bryostatin-1 administration in patients with recurrent or persistent platinum-sensitive epithelial ovarian cancer or primary peritoneal carcinoma.Methods. Eligible patients were randomized to receive either bryostatin-1 25μg/m2as a 1h infusion weekly for 3 weeks followed by a 1-week rest (Regimen I) or bryostatin-1 120μg/m2as a 72h continuous infusion every 2 weeks (Regimen II).Results. Fifty-five patients were enrolled on this study. There was one durable response among 27 eligible patients (response rate=3.7%) on Regimen II and no responses in the 27 eligible patients on Regimen I. Nineteen patients (eleven on Regimen I and eight on Regimen II) had stable disease. The most common adverse event was myalgia, with 12 of 27 patients (44%) on each regimen experiencing some degree of myalgia. There were no other significant toxicities on either treatment arm.Conclusions. Both of these schedules and doses of bryostatin-1 are inactive as single agents in previously treated epithelial ovarian cancer.
